Journal Articles

Donald and Barbara Zucker School of Medicine
Academic Works

2018

Reducing seed waste and increasing value of
dynamic intraoperative implantation of Pd-103
seeds in prostate brachytherapy
P. K. Taylor
Northwell Health

A, C. Riegel
Zucker School of Medicine at Hofstra/Northwell

Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Radiation Medicine Commons
Recommended Citation
Taylor PK, Riegel AC. Reducing seed waste and increasing value of dynamic intraoperative implantation of Pd-103 seeds in prostate
brachytherapy. . 2018 Jan 01; 19(5):Article 3042 [ p.]. Available from: https://academicworks.medicine.hofstra.edu/articles/3042.
Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more
information, please contact academicworks@hofstra.edu.

Received: 27 June 2017

|

Revised: 13 March 2018

|

Accepted: 2 May 2018

DOI: 10.1002/acm2.12404

RADIATION ONCOLOGY PHYSICS

Reducing seed waste and increasing value of dynamic
intraoperative implantation of Pd‐103 seeds in prostate
brachytherapy
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Abstract
Several nomograms exist for ordering palladium‐103 seeds for permanent prostate

2

Hofstra Northwell School of Medicine,
Hempstead, NY, USA

seed implants (PSI). Excess seeds from PSIs pose additional radiation safety risks and
increase the cost of care. This study compared ﬁve nomograms to clinical data from
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dynamic modiﬁed‐peripheral intraoperative PSI to determine (a) the cause of excess
seeds and (b) the optimal nomogram for our institution. Pre‐ and intraoperative
patient data were collected for monotherapy PSIs and compiled into a clinical database. All patients were prescribed 125 Gy with dose coverage of D90% = 100% to
the planning target volume (PTV) using

103

Pd seeds with mean air‐kerma strength

(SK ) of 2 U. Seeds were ordered based upon an in‐house nomogram as a function of
preoperative prostate volume and prescription dose. Preoperative prostate volume
was assessed with transrectal ultrasound. If any of the following four conditions
were not met: (a) preoperative volume = intraoperative volume, (b) D90% = 100%,
(c) SK ¼ 2U, and (d) seed ordering matched the in‐house nomogram, then a normalization factor was applied to the number of seeds used intraoperatively to meet all
four conditions. Four published nomograms, an in‐house nomogram, and the normalized number of implanted seeds for each patient were plotted against intraoperative
prostate volume. Of the 226 patients, 223 had excess seeds at the completion of
their PSI. On average, 25.7 ± 9.9% of ordered seeds were not implanted. Excess
seeds were separated into two categories, accounted‐for excess, determined by the
four normalization factors, and residual excess, assumed to be due to overordering.
The upper 99.9% CI linear ﬁt of the normalized clinical data plus a 5% “cushion” may
provide a more reasonable nomogram for

103

Pd seed ordering for our institution.

Nomograms customized for individual institutions may reduce seed waste, thereby
reducing radiation safety risks and increasing the value of prostate brachytherapy.
PACS
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1 | INTRODUCTION

ET AL.

quantity AXS is equal to the sum of the number of excess seeds
remaining after an implant (n) which can be attributed to a speciﬁc

Many treatment options, such as radical prostatectomy, external beam

reason (i) [eq. (2)]. The value of ni can be positive or negative.

radiation therapy (EBRT), brachytherapy, hormonal treatment, and active
surveillance, exist for patients with prostate cancer.1 Transperineal inter-

AXS ¼

stitial permanent prostate brachytherapy (TIPPB) for early stage prostate

X
i

ni

(2)

cancer is an outpatient procedure involving insertion of radioactive

Excess seeds that could not be attributed to a speciﬁc cause

seeds into the prostate under transrectal ultrasound guidance.1 Current

were considered “residual.” The quantity RXS is equal to the number

radioisotopes used in TIPPB include
institution,

125

I,

103

Pd, and

131

Cs.1–4 At our

103

Pd seeds are implanted using a dynamic intraoperative

of excess seeds less the number of accounted‐for excess seeds
[eq. (3)].

technique1–3 and the workﬂow for seed ordering, implantation, and
postimplant dosimetry is similar to that described in AAPM TG‐64.2 The
workﬂow is as follows: (a)

RXS ¼ NXS  AXS

103

Pd seeds are ordered using a nomogram
103

(3)

Pd seeds are indepen-

We identiﬁed four potential causes of excess seeds which are

dently assayed, (c) the 103Pd seeds are implanted into the prostate under

summarized in Table 1 and described in greater detail below. The

based on preoperative prostate volume, (b) the

transrectal ultrasound guidance, (d) postoperative excess 103Pd seeds (if

value nvol was calculated by taking the difference between the num-

applicable) are counted and disposed of by the medical physicist, and (e)

bers of seeds which should have been ordered for each respective

postoperative dosimetry is performed approximately 4 weeks later.

volume (preoperative and intraoperative) based upon the in‐house

Preoperative imaging of the patient's prostate is used to determine
103

nomogram. If preoperative prostate volume was greater than intra-

Pd seeds to be ordered. At our institution, a nomo-

operative prostate volume, additional, unnecessary seeds were

gram comparing total recommended air‐kerma strength (U) and prostate

ordered, i.e., nvol [ . If the intraoperative prostate volume was

the number of

volume (cm3) is used to determine the recommended total air‐kerma

greater than the preoperative volume, more seeds were used than

strength for the implant. The number of required seeds is found by

anticipated, which lowered the expected number of excess seeds at

dividing the total air‐kerma strength by the requested air‐kerma

the end of the procedure, i.e., nvol .

strength per seed. In our clinical experience, we have often found that
103

The value norder was the difference between what was ordered

Pd seeds after prostate

and what should have been ordered based on the in‐house nomo-

seed implants. Reducing the number of unused seeds can reduce radia-

gram and the preoperative prostate volume. The output of the

tion safety risks, reduce cost, and increase the value of prostate

nomogram is total recommended air‐kerma strength. When this

brachytherapy in the context of value‐based medicine, deﬁned as, “the

value is converted into number of seeds using vendor speciﬁed

practice of medicine incorporating the highest level of evidence‐based

air‐kerma strength per seed, it is not necessarily an integer. For sim-

data with the patient‐perceived value conferred by healthcare interven-

plicity in ordering and to insure enough seeds were present for the

tions for the resources expended.”5 The purpose of this study was, (a)

procedure, nomogram results were frequently rounded up to the

there are a substantial number of excess

determine the cause of excess

103

Pd seeds in dynamic intraoperative

TIPPB and (b) determine the optimal nomogram for our institution.

nearest multiple of ﬁve. If more seeds were ordered than indicated
by the nomogram, the result is a known excess compared to the
nomogram, i.e., norder . If fewer seeds were ordered than indicated by
the nomogram, the result is a known seed deﬁcit, i.e., norder .

2 | MATERIALS AND METHODS
Prostate cancer patients who received monotherapy using

103

Pd to a

dose of 125 Gy were retrospectively included in the chart review.

T A B L E 1 Variables which contribute to deviations between the
expected number of seeds used intraoperatively and actual number
of seeds used intraoperatively.

Relevant dosimetric and volumetric pre‐, intra‐, and postoperative
Reasons for
excess seeds

measurements were compiled into a clinical database.

2.A | Excess seeds
The clinical database was used to determine the number of excess seeds
for each patient. The number of excess seeds (NXS) is deﬁned in eq. (1).

NXS ¼ ðnumber of seeds orderedÞ
 ðnumber of seeds used intra  operativelyÞ

(1)

The total number of excess seeds can be separated into two categories, accounted‐for excess (AXS) and residual excess (RXS). The

Description

Number of excess
seeds due to
reason (i)

Change in
prostate volume

Preoperative prostate
volume ≠ intraoperative
prostate volume

nvol

Intraoperative
D90%

Intraoperative
D90% ≠ 100% (i.e., a “hot”
or “cold” implant)

nD90%

Mean air‐kerma
strength

Mean air‐kerma
strength (SK) ≠ 2 U per seed

nU

Ordering

Number of ordered
seeds deviated from
nomogram

norder
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All patients were prescribed 125 Gy with dose coverage of

Table 2 to determine ni and subsequently NXS, AXS, and RXS. A nega-

D90% = 100% to the planning target volume (PTV). If the intraoper-

tive sign in Table 3 indicates that variable contributed positively

ative D90% was less than 100%, i.e., a “cold implant,” then not

toward RXS, that is, there should have been more seeds at the end

enough seeds were used during the implant resulting in a known

of the procedure due to that speciﬁc variable.

seed excess at the end of the procedure, i.e., nD90% . If the intraoper-

Of the 226 prostate seed implants, 98.6% (n = 223) had excess

ative D90% was greater than 100%, more seeds were used than

seeds. On average (±1 standard deviation), there were 29.2 ± 13.2

anticipated which lowered the number of excess seeds at the end of

excess seeds after the completion of a prostate seed implant. On

the procedure, i.e., nD90% . If the mean air‐kerma strength (SK ) for a

average, 25.7 ± 9.9% of ordered seeds were not implanted. The per-

batch of seeds was greater than 2 U per seed, fewer seeds were

centage of ordered seeds which were wasted is the quotient of the

required to meet the prescription dose of D90% = 100% to the PTV

number of excess seeds to the number of seeds ordered (eq. 4). Fig-

resulting in a known seed excess, i.e., nU . If the mean air‐kerma

ure 1 shows the distribution of the percentage of ordered seeds

strength (SK ) for a batch of seeds was less than 2 U per seed, a

which were wasted.

greater number of seeds were required to meet the prescription
dose of D90% = 100% to the PTV resulting in a known seed deﬁcit,

Percentage of ordered seeds which were wasted =
# of excess seeds
 100%
# of seeds ordered

i.e., nU .

2.B | Clinical data normalization parameters

(4)

We found that none of the four parameters identiﬁed above

Once the cause of excess seeds was determined, the number of

contributed substantially to seed excess. In the cases where the

seeds used intraoperatively per patient was linearly normalized such

intraoperative volume was greater than preoperative volume (53% of

that SK ¼ 2 U and the intraoperative D90% was equal to 100%. The

implants, n = 117), more seeds were used than anticipated to

Pd seeds vs intraoperative prostate volume

accommodate the larger prostate. In the cases where the implant

for each patient was plotted against intraoperative prostate volume

had a D90% > 100%, i.e., a “hot implant” (72% of implants,

and the upper 99.9% conﬁdence interval of the patient data was

n = 159), more seeds were used than anticipated which should have

normalized number of

103

contributed towards the ﬁnal number of excess seeds. In the cases

generated.

where the mean air‐kerma strength was greater than 2 U (43% of
implants, n = 98), more seeds were used than anticipated which

3 | RESULTS

should have contributed towards the number of excess seeds. The

Between 2010 and 2015, our institution treated 251 patients with

i \0 means the number of residual‐excess seeds was on average
of n

value of ni was on average negative for each “i.” The consequence

TIPPB using

103

Pd to a dose of 125 Gy. Pre‐, intra‐, and postopera-

greater

than

the

physical

number

of

excess

seeds.

On

tive assessments were measured and compiled into a clinical data-

average, 30.7 ± 7.1% of ordered seeds were RXS. Table 4 shows the

base. For this study, exclusion criteria were: (a) an absolute

average NXS, RXS, and ni.

difference greater than 20% between the intra‐ and postoperative
D90% to the PTV (n = 20), (b) postoperative data were not available
(n = 2), and (c) the combined modality therapy (external beam radia-

3.2. | Nomogram

tion therapy and TIPPB) nomogram was used to order seeds (n = 3).

The clinical data, after being normalized such that SK ¼ 2U and

This left n = 226 patients in the study.

D90% = 100%, was compared to ﬁve nomograms: AAPM TG‐64,2
Anderson6 (Memorial‐Sloan Kettering Cancer Center, 1993), Stock3
(Mt. Sinai, 1995), Wang7, and our in‐house nomogram currently in

3.A | Excess seeds

use since 2010 (Fig. 2). There were differences between prescription

Table 2 lists patient‐speciﬁc assessments for three sample patients.

doses which required linear scaling, for example, Anderson uses a

Table 3 shows the calculation performed using the assessments in

prescription dose of 115 Gy for

103

Pd. If the AAPM TG‐64 or

T A B L E 2 Patient‐speciﬁc assessments for three sample patients.
Patient‐speciﬁc assessments

Patient

I
Preoperative
volume (cm3)

A

28.0

B

23.5

C

51.0

II
# of seeds to
order (Vol pre-op)
98

III
# of seeds
ordered

IV
Intraoperative
volume (cm3)

95

22.7

86

90

26.6

153

145

47.8

V
# of seeds to
order (Voli-o)
85

VI
# of seeds
used

VII

VIII

Mean SK (U)

D90%i-o

56

2.02

94.2

94

72

2.00

107.5

146

103

1.98

95.5
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T A B L E 3 Determination of residual‐excess (RXS) seeds for patients A, B, and C from Table 2.
Determination of RXS
Number of excess seeds due to i
Derivation using columns from Table 2

NXS
(III–VI)

nvol
(II–V)

norder
(III–II)

nD90%
(VI) 100%  1
VIII
3.5

A

39

13

−3

B

18

−8

4

−5.0

0.00

C

42

7

−8

4.9

−1.04

ð

Þ

nU
(VIÞ 1  2U
VII
0.55

ð

A
PXS
ni

Þ

i

RXS P
NXS  ni
i

14.05

24.9

−9

27.0

2.9

39.1

Frequency vs. Percent of ordered seeds which were unused
60

50

Frequency

40

30

20

10

0
0-5

5-10

10-15

15-20

20-25

25-30

30-35

35-40

40-45

45-50

Percent of ordered seeds per patient which were unused

F I G . 1 . Histogram indicating the
frequency of the percent of ordered seeds
which were unused per prostate seed
implant procedure.

T A B L E 4 Average number of excess seeds (NXS), number of excess seeds due to reason (i), and number of residual‐excess (RXS) seeds.
i  1ri
n

NXS

nvol

norder

nD90%

nU

RXS

29.2 ± 13.2

−0.6 ± 13.9

−1.1 ± 3.5

−3.4 ± 6.9

−0.1 ± 1.7

34.4 ± 9.3

Anderson nomogram had been used at our institution, approximately

to account for excess seeds, (a) variances between pre‐ and intraop-

50% of normalized clinical cases would not have had sufﬁcient

erative prostate volume, (b) differences between what was ordered

seeds.

and what should have been ordered based upon the nomogram, (c)

Figure 3 is a plot of the upper 99.9% conﬁdence interval (CI) of

D90% not being equal to 100%, and (d) mean air‐kerma strength not

the normalized clinical data, the upper 99.9% CI plus a 5% “cushion,”

being equal to 2 U. We found that none of these variables con-

the normalized clinical data, and the in‐house nomogram. If the

tributed substantially to the seed excess for our patient sample. The

Pd seed

average number of excess seeds was 29.2 ± 13.2 and the average

ordering, 12 out of 226 (5.3%) of normalized clinical cases would not

number of residual‐excess seeds was 34.4 ± 9.3. Overordering to

upper 99.9% CI of the normalized clinical was used for

103

have had sufﬁcient seeds for the implant. The upper 99.9% CI plus a

assure a sufﬁcient quantity of seeds during the prostate seed implant

5% overordering “cushion” would provide enough seeds for all but

procedure may be contributing to RXS. If the upper 99.9% CI nomo-

one patient.

gram was used, 12 patients would not have had enough seeds for
their procedure. If the upper 99.9% CI + 5% was used, one patient
would not have had enough seeds for their procedure and we could

4 | DISCUSSION

potentially reduce the number of ordered seeds by 13%.

Based upon the analysis of 226 patients spanning 6 yr, 25.7 ± 9.9%

nomograms overestimate the number of required seeds (in‐house

of ordered seeds were not implanted. As with most clinical proce-

nomogram and Stock3), two nomograms lay within the range of the

dures, there will be some discrepancy between what is planned and

clinical data (AAPM TG‐642 and Anderson6), and one underestimates

what occurs at the time of the procedure. We identiﬁed four vari-

the number of seeds required (Wang7). The disparity between nomo-

ables in the prostate seed implant ﬂow process which could be used

grams could be attributed to their variety in formulation. The

When the clinical data is compared to the other nomograms, two

TAYLOR
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70

75

Number of Pd-103 Seeds (2 U/seed)

Number of Pd-103 Seeds vs. Prostate Volume (125 Gy) [n = 226]

F I G . 2 . A comparison between four
published nomograms, an in‐house
nomogram, and the normalized clinical data
(n = 226) for a prescription dose of
125 Gy.
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55

60

65

Prostate Volume (cc)
AAPM TG-64 (2)

Stock R (3)

Anderson L (6)

Wang X (7)

In-house nomogram 2010-2015

Normalized Clinical Data

Number of Pd-103 Seeds (2 U/seed)

Number of Pd-103 Seeds vs. Prostate Volume (125 Gy) [n = 226]

F I G . 3 . A comparison of the upper
99.9% conﬁdence interval of the linear
regression of the normalized clinical data
compared to the in‐house nomogram.
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Prostate Volume (cm3)
In-house nomogram 2010-2015

Normalized Clinical Data

Upper 99.9% C.I.

Upper 99.9% C.I. + 5%

nomogram by Wang7 is a theoretical derivation where the prostate

evaluation using D90% as a volumetric dose metric. Given the dis-

is modeled as a sphere and radioactivity is considered to be in con-

parity between published nomograms, institution‐speciﬁc nomograms

tinuous form. The Anderson nomogram was generated from matched

may provide a more efﬁcient means to order and deliver TIPPB.

103

125

I implants evaluated

Reducing the number of excess seeds after a prostate seed

Our institution uses a modiﬁed peripheral loading technique, 3D

beneﬁts. The savings in US Dollars vs prostate volume is demon-

transrectal ultrasound, and dynamic intraoperative delivery.2 This 3D

strated in Fig. 4. The savings was calculated by determining the dif-

method allows the prostate, PTV, organs at risk, needles, seeds, and

ference in the number of seeds between the in‐house nomogram

dose distribution to be visualized in real time. It is possible the in‐

and the upper 99.9% CI + 5% “cushion.” This difference was multi-

house nomogram, which has been in use for nearly a decade, is not

plied by the 2016 Medicare payment rate of $66.23 per source

optimized for the current method of delivery. In the current work,

(HCPCS Code C2641: Brachytherapy source, non‐stranded, Palla-

peripheral dose of 13
as if

103

Pd implants and 64

implant is beneﬁcial in improving safety but it also yields ﬁnancial

6

Pd had been used.

we collected data spanning 6 yr from over 200

103

Pd patients to

dium‐103, per source). By applying the customized nomogram to our

reﬁne our seed ordering nomogram as per the American Brachyther-

sample, we could potentially reduce costs by approximately $43,000

apy Society1 and AAPM TG-1376 recommendations for plan

per year.

388
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US Dollars

Financial savings (USD) per patient vs. Prostate volume (cm3)
(HCPCS Code C2641: Brachytherapy source, non-stranded, Palladium-103, per source, 2016 Payment
Rate $66.23)

$1,700
$1,600
$1,500
$1,400
$1,300
$1,200
$1,100
$1,000
$900
$800
$700
$600
$500
$400
$300
$200
$100
$0
10

15

20

25

30

35

40

Prostate Volume

45

50

5 | CONCLUSION

60

patients, we found that over 85% of clinical cases wasted over 15%
of ordered seeds. Substantial disparity between published nomograms was observed. The upper 99.9% CI of our clinical data plus a
5% “cushion” may provide a more reasonable nomogram for

65
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